EMPO is thought to be one of the active metabolites of glimepiride, and it is believed to contribute to the medication’s blood sugar-lowering effects. EMPO has been studied extensively, and it has been shown to stimulate insulin secretion from pancreatic beta cells, similar to glimepiride. EMPO is also thought to have a longer half-life than glimepiride, which means it may have a more prolonged effect on blood sugar levels.
As with any medication, glimepiride may cause side effects, including low blood sugar, upset stomach, headache, and skin rash. If you experience any severe or persistent side effects, you should contact your doctor or seek medical attention right away.
